WEBULL
WebtradeDownload

Ascendis Pharma (ASND) Stock May Be Undervalued After Rare Disease Data News

Simply Wall St · 1d ago

Ascendis Pharma has seen its stock weaken in recent weeks, and that slide is putting fresh focus on whether the current share price lines up with what its earnings story can support. With new clinical data on key rare disease programs on the way, the question is how much of that potential is already embedded in the valuation.

  • The share price has fallen 15.3% over the past month, which puts recent optimism about Ascendis Pharma under pressure and brings the earnings backdrop into sharper focus.
  • Upcoming presentations on TransCon PTH and navepegriti may support expectations for future profit potential and cash generation from Ascendis Pharma's rare disease pipeline, which matters if you are anchoring value on its earnings power.
  • The analysts covering Ascendis Pharma have run their own numbers. See what analysts think Ascendis Pharma's shares could be worth.

The issue now is whether Ascendis Pharma's current stock price is appropriately aligned with what its earnings justify today.

If you are weighing whether Ascendis Pharma's earnings story justifies the recent share price slide, it can help to compare it with other 32 high quality undervalued stocks.

Does Ascendis Pharma Look Undervalued on Earnings?

P/E works quite well for Ascendis Pharma because investors are closely watching how its rare disease portfolio converts into earnings over time. On this basis, the stock trades at about 17.6x P/E, which is slightly above the broader biotech industry average of roughly 17.4x but below the peer group, which is closer to 26.6x. Compared with a tailored fair multiple that reflects Ascendis Pharma's own risk profile and fundamentals, this current P/E indicates that the shares are trading at a discount rather than a premium.

Because Ascendis Pharma is preparing to showcase new hypoparathyroidism and achondroplasia data at ASBMR 2026, the fact that the stock still trades below that bespoke fair P/E suggests the recent pullback has not erased the valuation gap that appears undervalued within this framework. For you as an investor, the key judgment is whether those earnings and cash flow expectations that underpin the fair multiple seem achievable enough to support relying on this P/E signal. Explore the numbers behind Ascendis Pharma's P/E valuation.

NasdaqGS:ASND P/E Ratio as at Oct 2026
NasdaqGS:ASND P/E Ratio as at Oct 2026

The Ascendis Pharma Narrative: What Would Justify Today's Price?

Narratives pick up where this valuation puzzle leaves off by explaining which future paths for Ascendis Pharma's growth, margins and earnings would need to occur for the stock to be worth materially more or materially less than it is today. These narratives can be found on Simply Wall St's Community page. Each one treats fair value as a specific, testable view on Ascendis Pharma's business that you can continue to track as new information emerges.

One of the top community narratives on Ascendis Pharma: 28% undervalued

"Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies…"

Discover why this Narrative puts Ascendis Pharma at 28% undervalued.

One more Ascendis Pharma check that belongs beside the price tag

Valuation only tells part of the story, because Simply Wall St's broader review has also highlighted specific concerns about Ascendis Pharma that deserve a look before you lean too hard on the earnings lens. Take a closer look at 1 major warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.